Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer’s disease

Research output: Contribution to journalArticle

Abstract

Background: Alzheimer’s disease (AD) is the most common cause of dementia in older patients. Rivastigmine, a reversible cholinesterase inhibitor, has been shown to improve the clinical manifestations of AD by delaying the breakdown of acetylcholine (ACh) released into synaptic clefts. Moreover, there is evidence that ACh modulates EEG alpha frequency. Objectives: the objectives of this pilot study in patients with AD were to determine the effects of two formulations of RV (transdermal and oral) on Mini-Mental State Examination (MMSE) scores and on alpha frequency in particular the posterior dominant rhythm. Methods: twenty subjects with AD were randomly assigned to receive either RV transdermal patch (RV-TDP, n=10) or RV capsules (RV-CP, n=10) according to the standard recommended dosage regimen. All patients were driven to the maximum drug dosage. Diagnosis of AD was made according to NINCDS-ADRDA criteria and the Diagnostic and Statistical Manual of Mental Disorders IV. All patients underwent EEG recordings at the beginning and at the end of the 18-month study period using P3, P4, O1 and O2 electrodes each at high (10.5-13.0 Hz) and low (8.0-10.5 Hz) frequency. MMSE scores were determined at the start of the study and at three successive 6-month intervals (T0, T1, T2, and T3). Results: administration of RV-DP increases the spectral power of alpha waves in the posterior region and is associated with improved cognitive function as evidenced by significant changes in MMSE scores. Conclusion: RV-DP provides an effective and long-term management option in patients with AD.

Original languageEnglish
Pages (from-to)72-83
Number of pages12
JournalAmerican Journal of Neurodegenerative Diseases
Volume3
Issue number2
Publication statusPublished - 2014

Fingerprint

Rivastigmine
Alpha Rhythm
Alzheimer Disease
Acetylcholine
Electroencephalography
Transdermal Patch
Cholinesterase Inhibitors
Diagnostic and Statistical Manual of Mental Disorders
Cognition
Capsules
Dementia
Electrodes

Keywords

  • Alpha rhythm oscillations
  • Alzheimer’s disease
  • MMSE scores
  • Rivastigmine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

@article{e209ba6744a641bdbd6c0762f127ec85,
title = "Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer’s disease",
abstract = "Background: Alzheimer’s disease (AD) is the most common cause of dementia in older patients. Rivastigmine, a reversible cholinesterase inhibitor, has been shown to improve the clinical manifestations of AD by delaying the breakdown of acetylcholine (ACh) released into synaptic clefts. Moreover, there is evidence that ACh modulates EEG alpha frequency. Objectives: the objectives of this pilot study in patients with AD were to determine the effects of two formulations of RV (transdermal and oral) on Mini-Mental State Examination (MMSE) scores and on alpha frequency in particular the posterior dominant rhythm. Methods: twenty subjects with AD were randomly assigned to receive either RV transdermal patch (RV-TDP, n=10) or RV capsules (RV-CP, n=10) according to the standard recommended dosage regimen. All patients were driven to the maximum drug dosage. Diagnosis of AD was made according to NINCDS-ADRDA criteria and the Diagnostic and Statistical Manual of Mental Disorders IV. All patients underwent EEG recordings at the beginning and at the end of the 18-month study period using P3, P4, O1 and O2 electrodes each at high (10.5-13.0 Hz) and low (8.0-10.5 Hz) frequency. MMSE scores were determined at the start of the study and at three successive 6-month intervals (T0, T1, T2, and T3). Results: administration of RV-DP increases the spectral power of alpha waves in the posterior region and is associated with improved cognitive function as evidenced by significant changes in MMSE scores. Conclusion: RV-DP provides an effective and long-term management option in patients with AD.",
keywords = "Alpha rhythm oscillations, Alzheimer’s disease, MMSE scores, Rivastigmine",
author = "Moretti, {Davide V.}",
year = "2014",
language = "English",
volume = "3",
pages = "72--83",
journal = "American Journal of Neurodegenerative Diseases",
issn = "2165-591X",
publisher = "e-Century Publishing Corporation",
number = "2",

}

TY - JOUR

T1 - Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer’s disease

AU - Moretti, Davide V.

PY - 2014

Y1 - 2014

N2 - Background: Alzheimer’s disease (AD) is the most common cause of dementia in older patients. Rivastigmine, a reversible cholinesterase inhibitor, has been shown to improve the clinical manifestations of AD by delaying the breakdown of acetylcholine (ACh) released into synaptic clefts. Moreover, there is evidence that ACh modulates EEG alpha frequency. Objectives: the objectives of this pilot study in patients with AD were to determine the effects of two formulations of RV (transdermal and oral) on Mini-Mental State Examination (MMSE) scores and on alpha frequency in particular the posterior dominant rhythm. Methods: twenty subjects with AD were randomly assigned to receive either RV transdermal patch (RV-TDP, n=10) or RV capsules (RV-CP, n=10) according to the standard recommended dosage regimen. All patients were driven to the maximum drug dosage. Diagnosis of AD was made according to NINCDS-ADRDA criteria and the Diagnostic and Statistical Manual of Mental Disorders IV. All patients underwent EEG recordings at the beginning and at the end of the 18-month study period using P3, P4, O1 and O2 electrodes each at high (10.5-13.0 Hz) and low (8.0-10.5 Hz) frequency. MMSE scores were determined at the start of the study and at three successive 6-month intervals (T0, T1, T2, and T3). Results: administration of RV-DP increases the spectral power of alpha waves in the posterior region and is associated with improved cognitive function as evidenced by significant changes in MMSE scores. Conclusion: RV-DP provides an effective and long-term management option in patients with AD.

AB - Background: Alzheimer’s disease (AD) is the most common cause of dementia in older patients. Rivastigmine, a reversible cholinesterase inhibitor, has been shown to improve the clinical manifestations of AD by delaying the breakdown of acetylcholine (ACh) released into synaptic clefts. Moreover, there is evidence that ACh modulates EEG alpha frequency. Objectives: the objectives of this pilot study in patients with AD were to determine the effects of two formulations of RV (transdermal and oral) on Mini-Mental State Examination (MMSE) scores and on alpha frequency in particular the posterior dominant rhythm. Methods: twenty subjects with AD were randomly assigned to receive either RV transdermal patch (RV-TDP, n=10) or RV capsules (RV-CP, n=10) according to the standard recommended dosage regimen. All patients were driven to the maximum drug dosage. Diagnosis of AD was made according to NINCDS-ADRDA criteria and the Diagnostic and Statistical Manual of Mental Disorders IV. All patients underwent EEG recordings at the beginning and at the end of the 18-month study period using P3, P4, O1 and O2 electrodes each at high (10.5-13.0 Hz) and low (8.0-10.5 Hz) frequency. MMSE scores were determined at the start of the study and at three successive 6-month intervals (T0, T1, T2, and T3). Results: administration of RV-DP increases the spectral power of alpha waves in the posterior region and is associated with improved cognitive function as evidenced by significant changes in MMSE scores. Conclusion: RV-DP provides an effective and long-term management option in patients with AD.

KW - Alpha rhythm oscillations

KW - Alzheimer’s disease

KW - MMSE scores

KW - Rivastigmine

UR - http://www.scopus.com/inward/record.url?scp=84980054116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980054116&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84980054116

VL - 3

SP - 72

EP - 83

JO - American Journal of Neurodegenerative Diseases

JF - American Journal of Neurodegenerative Diseases

SN - 2165-591X

IS - 2

ER -